News - Valeant Pharmaceuticals, Genito-urinary


Popular Filters

1 to 25 of 90 results

US FDA approves NDA from Actavis and Valeant

US FDA approves NDA from Actavis and Valeant


US generics major Actavis and Canada’s Valeant Pharmaceuticals said that the US Food and Drug Administration…

ActavisCanadaGenericsMetronidazolePharmaceuticalRegulationUSAValeant PharmaceuticalsWomen's Health

Valeant Pharma returns to profit, boosted by B&L acquisition


Canadian drugmaker Valeant Pharmaceuticals International has announces fourth quarter financial results…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Teva launches authorized generic of Detrol in USA

Teva launches authorized generic of Detrol in USA


Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, says it has launched…

Detrol LAGenericsGenito-urinaryMarkets & MarketingNorth AmericaPfizerTeva Pharmaceutical IndustriesUSA

Patent settlements for Pfizer/Teva and Mylan/Eisai

Patent settlements for Pfizer/Teva and Mylan/Eisai


US pharma behemoth Pfizer says it has settled its long-standing litigation against a US subsidiary of…

Banner PharmacapsEisaiGenericsLegalMen's HealthMylan LaboratoriesNorth AmericaOncologyPatentsPfizerTargretinTeva Pharmaceutical IndustriesValeant PharmaceuticalsViagra

Positive top-line Ph III results with ceftolozane/tazobactam in cUTI


US biopharma company Cubist Pharmaceuticals has revealed positive top-line results from its pivotal Phase…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsGenito-urinaryPharmaceuticalResearchtazobactam

Valeant agrees $142.5 million settlement with Anacor


Anacor Pharmaceuticals says it has entered into a $142,5 million settlement agreement with Canada-based…

Anacor PharmaceuticalsFinancialLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Anacor Pharma awarded $100 million damages


Anacor Pharmaceuticals says that the arbitrator appointed to resolve its dispute with Canada-based Valeant…

Anacor PharmaceuticalsLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

SOBI gains rights to distribute Ravicti in Middle East


Swedish Orphan Biovitrum says Hyperion Therapeutics has granted it exclusive rights to distribute its…

Genito-urinaryHyperion TherapeuticsLicensingPharmaceuticalRavictiRest of the WorldSobiSwedish Orphan Biovitrum

UK MHRA licenses Allergan's Botox for use in patients with overactive bladder


Botox (botulinum toxin type A), from US drugmaker Allergan (NYSE: AGN), has been licensed by the UK Medicines…


Valeant Pharma beats forecasts, turns in profit


Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) announced second quarter financial…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Valeant confirms plan to acquire Bausch & Lomb in a $8.7 billion transaction


Following speculation ahead of the extended holiday weekend, acquisitive Canadian drugmaker Valeant Pharmaceuticals…

Bausch & LombMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

Netherlands first to approve Astellas' Vesomni


The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says that the Dutch Medicines…

Astellas PharmaEuropeGenito-urinaryPharmaceuticalRegulationVesomni

NovaBay Pharmaceuticals: tuning in for a crescendo of data, say analysts


US biotech firm NovaBay Pharmaceutical's (Nasdaq: NBY) first-quarter 2013 results set the scene for a…

Antibiotics and Infectious diseasesauricloseneBiotechnologyFinancialGenito-urinaryNovaBay PharmaceuticalNVC-422OphthalmicsResearch

Drais Pharma to develop third Astellas compound through Tacurion


Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into…

ASP7035Astellas PharmaDrais PharmaceutialsGenito-urinaryLicensingPharmaceuticalResearchTacurion

Actavis and Valeant report first quarter 2013 results


US generics drug major Actavis (NYSE: ACT) and Canada's Valeant Pharmaceuticals (TSX: VRX) both presented…

ActavisFinancialGenericsValeant Pharmaceuticals

Auxilium Pharma acquires Actient in $585 million deal


Specialty drugmaker Auxilium Pharmaceuticals (Nasdaq: AUXL) says that it has completed the acquisition…

Actient PharmaAuxilium PharmaceuticalsGenito-urinaryMen's HealthMergers & AcquisitionsPharmaceutical

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?


US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Positive data expected for RedHill Biopharma's Crohn's disease candidate


Analysts at Roth Capital Partners have launched coverage of Israel-based specialty pharma company RedHill…

FinancialGenito-urinaryPharmaceuticalRBH-104RedHill BiopharmaResearch

Actavis settles with Valeant to launch generic Ziana and Zyclara in USA


US generics drug major Actavis (NYSE: ACT) has reached settlement agreements with Medicis Pharmaceutical,…

ActavisGenericsMarkets & MarketingNorth AmericaPatentsValeant PharmaceuticalsZiana GelZyclara

1 to 25 of 90 results

Back to top